These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 35028710)

  • 1. Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.
    Schrader AMR; de Groen RAL; Willemze R; Jansen PM; Quint KD; van Wezel T; van Eijk R; Ruano D; Tensen CP; Hauben E; Woei-A-Jin FJSH; Busschots AM; van den Berg A; Diepstra A; Vermeer MH; Vermaat JSP
    Virchows Arch; 2022 Mar; 480(3):667-675. PubMed ID: 35028710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified.
    Cho I; Yoon N; Hyeon J; Sim J; Yoo HY; Kim SJ; Kim WS; Ko YH
    Appl Immunohistochem Mol Morphol; 2020; 28(10):731-740. PubMed ID: 32287077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
    Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
    Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia.
    Phang KC; Akhter A; Tizen NMS; Rahman FA; Zahratul Azma R; Elyamany G; Shabani-Rad MT; Masir N; Mansoor A
    J Clin Pathol; 2018 Mar; 71(3):215-220. PubMed ID: 28775174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature.
    Lee J; Hue SS; Ko SQ; Tan SY; Liu X; Girard LP; Chan EHL; De Mel S; Jeyasekharan A; Chee YL; Koh LP; Poon LM
    Expert Rev Hematol; 2019 Dec; 12(12):1095-1105. PubMed ID: 31592693
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas.
    Uccella S; Goteri G; Maiorana A; Donati V; Tibiletti MG; Magnoli F; Facchi S; Merchiori D; Morsia E; Papotti R; Bettelli S; Forti E; Galimberti S; Rupoli S; Filosa A; Dardanis D; Bomben R; Braglia L; Pozzi S; Sacchi S
    Hum Pathol; 2023 Jun; 136():44-55. PubMed ID: 36997030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms.
    Hwang HS; Yoon DH; Hong JY; Park CS; Lee YS; Ko YH; Kim SJ; Kim WS; Suh C; Huh J
    Ann Hematol; 2018 Dec; 97(12):2363-2372. PubMed ID: 30069703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma.
    Cretella P; Peluso AL; Picariello C; Cozzolino I; Triggiani M; Puzziello A; Giudice V; Sabbatino F; Ieni A; Zeppa P; Caputo A
    Pathol Res Pract; 2022 Mar; 231():153804. PubMed ID: 35183824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series.
    Zamò A; Gerhard-Hartmann E; Ott G; Anagnostopoulos I; Scott DW; Rosenwald A; Rauert-Wunderlich H
    Virchows Arch; 2022 Dec; 481(6):935-943. PubMed ID: 36219238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.
    Abdulla M; Hollander P; Pandzic T; Mansouri L; Ednersson SB; Andersson PO; Hultdin M; Fors M; Erlanson M; Degerman S; Petersen HM; Asmar F; Grønbaek K; Enblad G; Cavelier L; Rosenquist R; Amini RM
    Am J Hematol; 2020 Jan; 95(1):57-67. PubMed ID: 31659781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary central nervous system lymphoma: Comprehension of cell-of-origin subtypes.
    Rao S; Epari S; Shet TM; Gujral S; Jain H; Bagal B; Senagar M; Shetty P; Moiyadi A; Goda JS; Gupta T
    Indian J Pathol Microbiol; 2023; 66(3):549-555. PubMed ID: 37530337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immunohistochemical study of diffuse large B-cell lymphoma with molecular subtyping based on Hans algorithm.
    Ananthamurthy A; Murali M
    Indian J Pathol Microbiol; 2024 Jul; 67(3):564-568. PubMed ID: 38394429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases.
    Menguy S; Beylot-Barry M; Parrens M; Ledard AP; Frison E; Comoz F; Battistella M; Szablewski V; Balme B; Croue A; Franck F; Ortonne N; Tournier E; Lamant L; Carlotti A; De Muret A; Le Gall F; Lorton MH; Merlio JP; Vergier B
    Histopathology; 2019 Jun; 74(7):1067-1080. PubMed ID: 30715765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Schrader AMR; Jansen PM; Vermeer MH; Kleiverda JK; Vermaat JSP; Willemze R
    Am J Surg Pathol; 2018 Nov; 42(11):1488-1494. PubMed ID: 30113335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg-type and other: an update on morphology and treatment.
    Paulli M; Lucioni M; Maffi A; Croci GA; Nicola M; Berti E
    G Ital Dermatol Venereol; 2012 Dec; 147(6):589-602. PubMed ID: 23149705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes.
    Lucioni M; Pescia C; Bonometti A; Fraticelli S; Moltrasio C; Ramponi A; Riboni R; Roccio S; Ferrario G; Arcaini L; Goteri G; Berti E; Paulli M
    Hum Pathol; 2021 May; 111():1-9. PubMed ID: 33548250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
    Batlle-López A; González de Villambrosía S; Francisco M; Malatxeberria S; Sáez A; Montalban C; Sánchez L; Garcia J; González-Barca E; López-Hernández A; Ruiz-Marcellan MC; Mollejo M; Grande C; Richards KL; Hsi ED; Tzankov A; Visco C; Xu-Monette ZY; Cao X; Young KH; Piris MÁ; Conde E; Montes-Moreno S
    Oncotarget; 2016 Apr; 7(14):18036-49. PubMed ID: 26910115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL.
    Perfecto-Avalos Y; Garcia-Gonzalez A; Hernandez-Reynoso A; Sánchez-Ante G; Ortiz-Hidalgo C; Scott SP; Fuentes-Aguilar RQ; Diaz-Dominguez R; León-Martínez G; Velasco-Vales V; Cárdenas-Escudero MA; Hernández-Hernández JA; Santos A; Borbolla-Escoboza JR; Villela L
    J Transl Med; 2019 Jun; 17(1):198. PubMed ID: 31185999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
    Montalbán C; Díaz-López A; Martín A; Baile M; Sanchez JM; Sancho JM; García O; Novelli S; Monter-Rovira A; Salar A; Bastos M; Gutiérrez A; Bento L; Córdoba R; Arquero T; González de Villambrosia S; Barranco G; De Oña R; López Guillermo A; Rodriguez Salazar MJ; Domínguez JF; Fernández R; Queizan JA; Rodríguez J; Abraira V; García JF;
    Br J Haematol; 2018 Aug; 182(4):534-541. PubMed ID: 29978453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.